Reply from the author  by Agarwal, Rajiv
Letters to the Editor1612
one member only had IgAN and one (or two relatives) tive treatments were very similar (i.e., 1.14 vs. 0.94 ng/mL/
had HSP. hour). Second, sodium intake was high and uncontrolled,
In our opinion, the possibility of such familial cases of allowing a lower baseline sodium excretion (intake)
IgAN and HSP can also be considered as another link before losartan treatment compared to placebo treat-
between the two diseases. ment ( sodium excretion 37 mEq/24 hours) and a higher
sodium excretion at the end of losartan treatment ( so-
Micheline Levy dium excretion 12 mEq/24 hours). Furthermore, the cir-
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Therefore, the most plausible explanation for the
plasma renin data obtained by Agarwal [1] may be meth-REFERENCES
odological shortcomings and random fluctuations, but
1. David J-C, ten Berge IJ, Weening JJ: What is the difference be- no real effect of losartan. Parenthetically, this could
tween IgA nephropathy and Henoch-Scho¨nlein purpura nephritis?
also hold true for the results of glomerular filtrationKidney Int 59:823–834, 2001
2. Levy M, French Cooperative Group of the Society of Nephrol- rate (GFR) measurements, where GFR decreased (ran-
ogy: Familial cases of Berger’s disease and anaphylactoid purpura: domly) by 5 mL/min during placebo treatment (from 69
More frequent than previously thought. Am J Med 87:246–248, 1989
to 64 mL/min) and increased by 5 mL/min during losar-3. Levy M: Multiplex families in IgA nephropathy. Contrib Nephrol
104:46–53, 1993 tan treatment (from 63 to 68 mL/min) [1].
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receptor blockage?
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expression severalfold from baseline [2]. Furthermore,
both 100 mg losartan and 80 mg quinalapril given for 10
days at this constant dose increased plasma renin activity
Reply from the author3- to 4-fold in 25 normotensive subjects on a controlled
I agree with Kra¨mer et al that the increase in plasma(low) sodium intake [3]. Finally, Stergiou et al recently
renin activity (PRA) with add-on losartan therapy wasdemonstrated that the addition of 80 mg valsartan for 5
unexpected [1]. However, I am unaware of any data inweeks to a maximal dose of chronic benazepril (20 mg
the population of patients that was studied to refute thosefor 6 weeks) significantly increased plasma renin activity
findings. Brown, Agirbasli, and Vaughan compared an-in 20 patients with primary hypertension [4].
giotensin-converting enzyme (ACE) inhibitors with an-The above results of Agarwal [1] may be explained by
giotensin II receptor blocker but did not study the combi-several shortcomings of this study. First, baseline plasma
nation in normotensive, sodium-restricted volunteers [2].renin activity before losartan treatment was 204% (!) of
In the study by Stergiou et al, benazepril was used in abaseline plasma renin activity before placebo treatment,
submaximal dose (20 mg/day) in patients with essentialwhereas plasma renin activities at the end of the respec-
hypertension [3]. In contrast, our patients received lisino-
pril for an average of 18 months in a dose of 40 mg/day
prior to participation in the trial. Such a dose is truly max- 2001 by the International Society of Nephrology
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imal, especially when considering the fact that elimina- pected. We do not have all the answers, but we speculate
on the reasons that this may have occurred [1]. Further-tion of lisinopril is predominantly renal and patients had
more, the primary end point of our trial was proteinuria,impaired glomerular filtration rates (GFR) [4]. Further-
not perturbations in renin-angiotensin system or GFR.more, our patients with chronic renal failure were con-
Thus, the results of our secondary outcomes should besuming a self-selected diet (one high in sodium), they were
considered exploratory, not definitive. We agree that ourobese, and they had poorly controlled hypertension de-
results do not fit the paradigm and that this needs furtherspite more than three medications. Therefore, this popu-
research.lation, which is reflective of a large population of the
chronic renal failure patients in the United States, is sub-
Rajiv Agarwalstantially different from those mentioned by Kra¨mer et al. Indianapolis, IN, USA
Our baseline PRA levels appear different, however,
Correspondence to Rajiv Agarwal, M.D., Clinical Associate Profes-because in the trial design (randomized two-period cross-
sor of Medicine, Indiana University, VA-111N, 1481 West 10th Street,
over) these PRA baselines, prior to losartan therapy, Indianapolis, IN 46202, USA.
E-mail: ragarwal@iupui.eduwere obtained six weeks apart. We conducted analysis
as suggested by Rosner for crossover trials and excluded
REFERENCEScarryover or sequence effects [5]. The statistical analysis
of our data demonstrates that the likelihood of random 1. Agarwal R: Add-on angiotensin receptor blockade with maximized
ACE inhibition. Kidney Int 59:2282–2289, 2001chance accounting for our results of reduced PRA is
2. Brown NJ, Agirbasli M, Vaughan DE: Comparative effect of
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1 receptor antagonism on plasma fibrinolytic balance in humans.port these findings. Similarly, urinary sodium excretion
Hypertension 34:285–290, 1999did not change statistically and is unlikely to account for 3. Stergiou GS, Skeva II, Baibas NM, et al: Additive hypotensive
our findings. The chance of random error causing GFR effect of angiotensin-converting enzyme inhibition and angiotensin-
receptor antagonism in essential hypertension. J Cardiovasc Phar-changes is 1.7%. As to the method of blood sampling
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for PRA, all samples were drawn in the morning after 4. Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angio-
tensin converting enzyme (ACE) inhibitors in renal failure. Clina half hour of supine rest in a quiet room.
Pharmacokinet 24:230–254, 1993Thus, I believe that our data are not due to methodo- 5. Rosner B: Fundamental of Biostatistics, 4th ed, Belmont, CA, Dux-
logic flaws or randomness, but they were certainly unex- bury Press, 1995
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